306 related articles for article (PubMed ID: 34359771)
1. Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma.
Eddy K; Chen S
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359771
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1
Shah R; Singh SJ; Eddy K; Filipp FV; Chen S
Cancer Res; 2019 Apr; 79(8):1799-1809. PubMed ID: 30987979
[TBL] [Abstract][Full Text] [Related]
3. Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.
Martino JJ; Wall BA; Mastrantoni E; Wilimczyk BJ; La Cava SN; Degenhardt K; White E; Chen S
Oncogene; 2013 Sep; 32(37):4366-76. PubMed ID: 23085756
[TBL] [Abstract][Full Text] [Related]
4. Functional effects of GRM1 suppression in human melanoma cells.
Wangari-Talbot J; Wall BA; Goydos JS; Chen S
Mol Cancer Res; 2012 Nov; 10(11):1440-50. PubMed ID: 22798429
[TBL] [Abstract][Full Text] [Related]
5. Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.
Teh JL; Shah R; La Cava S; Dolfi SC; Mehta MS; Kongara S; Price S; Ganesan S; Reuhl KR; Hirshfield KM; Karantza V; Chen S
Breast Cancer Res Treat; 2015 May; 151(1):57-73. PubMed ID: 25859923
[TBL] [Abstract][Full Text] [Related]
6. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.
Marín YE; Namkoong J; Cohen-Solal K; Shin SS; Martino JJ; Oka M; Chen S
Cell Signal; 2006 Aug; 18(8):1279-86. PubMed ID: 16305822
[TBL] [Abstract][Full Text] [Related]
8. Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.
Wen Y; Li J; Koo J; Shin SS; Lin Y; Jeong BS; Mehnert JM; Chen S; Cohen-Sola KA; Goydos JS
Cancer Res; 2014 May; 74(9):2499-509. PubMed ID: 24491800
[TBL] [Abstract][Full Text] [Related]
9. Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression.
Rosenberg SA; Niglio SA; Salehomoum N; Chan JL; Jeong BS; Wen Y; Li J; Fukui J; Chen S; Shin SS; Goydos JS
Transl Oncol; 2015 Feb; 8(1):1-9. PubMed ID: 25749171
[TBL] [Abstract][Full Text] [Related]
10. PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.
Corrales E; Levit-Zerdoun E; Metzger P; Mertes R; Lehmann A; Münch J; Lemke S; Kowar S; Boerries M
Cell Commun Signal; 2022 Nov; 20(1):187. PubMed ID: 36434616
[TBL] [Abstract][Full Text] [Related]
11. Metabotropic glutamate receptor 1 mediates melanocyte transformation via transactivation of insulin-like growth factor 1 receptor.
Teh JL; Shah R; Shin SS; Wen Y; Mehnert JM; Goydos J; Chen S
Pigment Cell Melanoma Res; 2014 Jul; 27(4):621-9. PubMed ID: 24628914
[TBL] [Abstract][Full Text] [Related]
12. Implications of a Neuronal Receptor Family, Metabotropic Glutamate Receptors, in Cancer Development and Progression.
Eddy K; Eddin MN; Fateeva A; Pompili SVB; Shah R; Doshi S; Chen S
Cells; 2022 Sep; 11(18):. PubMed ID: 36139432
[TBL] [Abstract][Full Text] [Related]
13. Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.
Pollock PM; Cohen-Solal K; Sood R; Namkoong J; Martino JJ; Koganti A; Zhu H; Robbins C; Makalowska I; Shin SS; Marin Y; Roberts KG; Yudt LM; Chen A; Cheng J; Incao A; Pinkett HW; Graham CL; Dunn K; Crespo-Carbone SM; Mackason KR; Ryan KB; Sinsimer D; Goydos J; Reuhl KR; Eckhaus M; Meltzer PS; Pavan WJ; Trent JM; Chen S
Nat Genet; 2003 May; 34(1):108-12. PubMed ID: 12704387
[TBL] [Abstract][Full Text] [Related]
14. AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1).
Shin SS; Wall BA; Goydos JS; Chen S
Pigment Cell Melanoma Res; 2010 Feb; 23(1):103-11. PubMed ID: 19843246
[TBL] [Abstract][Full Text] [Related]
15. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.
Namkoong J; Shin SS; Lee HJ; Marín YE; Wall BA; Goydos JS; Chen S
Cancer Res; 2007 Mar; 67(5):2298-305. PubMed ID: 17332361
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer effect of metabotropic glutamate receptor 1 inhibition in human glioma U87 cells: involvement of PI3K/Akt/mTOR pathway.
Zhang C; Yuan XR; Li HY; Zhao ZJ; Liao YW; Wang XY; Su J; Sang SS; Liu Q
Cell Physiol Biochem; 2015; 35(2):419-32. PubMed ID: 25613036
[TBL] [Abstract][Full Text] [Related]
17. Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Lee HJ; Wall BA; Wangari-Talbot J; Shin SS; Rosenberg S; Chan JL; Namkoong J; Goydos JS; Chen S
Clin Cancer Res; 2011 Nov; 17(22):7080-92. PubMed ID: 21844014
[TBL] [Abstract][Full Text] [Related]
18. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Shoushtari AN; Chatila WK; Arora A; Sanchez-Vega F; Kantheti HS; Rojas Zamalloa JA; Krieger P; Callahan MK; Betof Warner A; Postow MA; Momtaz P; Nair S; Ariyan CE; Barker CA; Brady MS; Coit DG; Rosen N; Chapman PB; Busam KJ; Solit DB; Panageas KS; Wolchok JD; Schultz N
Clin Cancer Res; 2021 Apr; 27(8):2226-2235. PubMed ID: 33509808
[TBL] [Abstract][Full Text] [Related]
20. The PIK3CA H1047R Mutation Confers Resistance to BRAF and MEK Inhibitors in A375 Melanoma Cells through the Cross-Activation of MAPK and PI3K-Akt Pathways.
Candido S; Salemi R; Piccinin S; Falzone L; Libra M
Pharmaceutics; 2022 Mar; 14(3):. PubMed ID: 35335966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
